Featured Research

from universities, journals, and other organizations

Mild-mannered metabolic helper rushes to fight invading viruses, researchers report

Date:
May 9, 2010
Source:
Children's Hospital Boston
Summary:
Within cells, an ancient antiviral duo can deliver a one-two knockout to thwart invading viruses, report researchers who have just unmasked the cellular sidekick that throws the first punch. The findings mean scientists must rethink the design of antiviral immunity and how the body fends off viruses of all types, including influenza and HIV.

Within cells, an ancient antiviral duo can deliver a one-two knockout to thwart invading viruses, report researchers who have just unmasked the cellular sidekick that throws the first punch. The findings mean scientists must rethink the design of antiviral immunity and how the body fends off viruses of all types, including influenza and HIV.

In the study, Children's Hospital Boston researchers found, mild-mannered organelles inside the cell known as peroxisomes can detect virus invasion signals and launch a limited antiviral offensive. Other organelles, the mitochondria, follow up with a more definitive antiviral counterattack.

"This is the first demonstration that peroxisomes are involved in immunity," said Jonathan Kagan, staff scientist in the gastroenterology division and senior author of the paper published May 6 in the online journal Cell. "This work has implications for our understanding of how we interact with infectious viruses and even bacteria."

The paper establishes a new function for peroxisomes as a cellular compartment that promotes a rapid response to viral infection. With this discovery, the researchers say, scientists need to look for other cellular parts that may do double duty as pathogen detectors. A larger volunteer army may be lurking in cells as needed for the innate immune system.

In a clinical implication, the findings suggest a new approach to rare and largely untreatable conditions known as peroxisome biogenesis disorders, Kagan said. In the most common manifestation, Zellweger syndrome, children suffer from major developmental abnormalities and die as infants. The milder disorders allow children to live into their teens. Many affected children die of lung infections such as pneumonia, which may arise from problems in the antiviral signaling scaffold due to the absence of peroxisomes, Kagan speculates. Previously, the disorders have been considered developmental and metabolic.

When they are not fighting invading microbes, peroxisomes are busy mopping up the potentially damaging free radical byproducts produced by their larger distant cousins, mitochondria, the power plants of the cell. In other house-keeping duties, peroxisomes also make and attach the lipids that grease the cellular machinery so proteins can slide into or through membranes. Both organelles grow, multiply, and shrink in response to metabolic demands.

Peroxisomes acquire their virus-fighting power from a cloak of mitochondrial antiviral signaling protein, or MAVS. Five years ago, MAVS proteins were discovered on mitochondria, a surprising location for which they were named, and shown to be vital to the immune system's ability to fight infections.

MAVS proteins are found in all cells in the body, Kagan said, but until now they were only known to be draped around mitochondria. The latest study started as a search for MAVS on peroxisomes, an idea born from recent reports of other proteins shared by peroxisomes and mitochondria. On a graduate studies sabbatical from Vienna, first author Evelyn Dixit stained cells for MAVS and found the proteins on peroxisomes.

Next, she observed, the same MAVS proteins activated different antiviral immune responses, depending upon the organelle they adorned. "The difference was that the antiviral response was quicker and transient when it originated from peroxisomes compared to mitochondria," Dixit said.

In another difference, the peroxisomal MAVS turned on a subset of antiviral genes without a secreting interferon. By contrast, mitochondrial MAVS triggers interferon production and release, which alerts both the cell and its neighbors to mount a larger immune response.

"Seeing interferon-stimulated genes but no interferon was at first quite aggravating," Dixit said. "We thought we did something wrong. Then we had to turn our thinking around 180 degrees and accept that it was not a mistake. Peroxisomal MAVS leads to interferon-stimulated genes while bypassing interferon secretion."

The differential response may be a way that different kinds of cells can customize their antiviral responses to the special needs of different tissues, Kagan suggests. For example, the interferon response shuts down protein synthesis, promotes inflammation, and causes a general toxic effect that some tissues may be able to handle better than others, such as the intestines.

Without interferon, peroxisomes could mount a limited response in sensitive tissues, such as nerves, eyes, or heart muscle. "We have speculated that certain tissues may only use mitochondria or only use peroxisomes," Kagan said.

"At the end of the day, we found antiviral signaling can occur from peroxisomes and from mitochondria," he said. "Only from the peroxisome do we see a rapid response, and that is sufficient to control viruses, but it cannot eliminate them. Signaling from both is needed to effectively knock them out."


Story Source:

The above story is based on materials provided by Children's Hospital Boston. Note: Materials may be edited for content and length.


Journal Reference:

  1. Evelyn Dixit, Steeve Boulant, Yijing Zhang, Amy S. Lee, Charlotte Odendall, Bennett Shum, Nir Hacohen, Zhijian J. Chen, Sean P. Whelan, Marc Fransen, Max L. Nibert, Giulio Superti-Furga, and Jonathan C. Kagan. Peroxisomes Are Signaling Platforms for Antiviral Innate Immunity. Cell, 2010; DOI: 10.1016/j.cell.2010.04.018

Cite This Page:

Children's Hospital Boston. "Mild-mannered metabolic helper rushes to fight invading viruses, researchers report." ScienceDaily. ScienceDaily, 9 May 2010. <www.sciencedaily.com/releases/2010/05/100507151549.htm>.
Children's Hospital Boston. (2010, May 9). Mild-mannered metabolic helper rushes to fight invading viruses, researchers report. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/05/100507151549.htm
Children's Hospital Boston. "Mild-mannered metabolic helper rushes to fight invading viruses, researchers report." ScienceDaily. www.sciencedaily.com/releases/2010/05/100507151549.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins